Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O60741: Variant p.Met305Leu

Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1
Gene: HCN1
Feedback?
Variant information Variant position: help 305 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Methionine (M) to Leucine (L) at position 305 (M305L, p.Met305Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In DEE24; absence of hyperpolarization-activated currents; highly reduced amount of protein at the cell membrane. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 305 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 890 The length of the canonical sequence.
Location on the sequence: help FHMTYDLASAVVRIFNLIGM M LLLCHWDGCLQFLVPLLQDF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         FHMTYDLASAVVRIFNLIGMMLLLCHWDGCLQFLVPLLQDF

Mouse                         FHMTYDLASAVVRIFNLIGMMLLLCHWDGCLQFLVPLLQDF

Rat                           FHMTYDLASAVVRIFNLIGMMLLLCHWDGCLQFLVPLLQDF

Rabbit                        FHMTYDLASAVVRIFNLIGMMLLLCHWDGCLQFLVPLLQDF

Fission yeast                 LRQTLDSEST-------------------------------
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 890 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1
Transmembrane 296 – 318 Helical; Name=Segment S5
Helix 291 – 321



Literature citations
HCN1 mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond.
Marini C.; Porro A.; Rastetter A.; Dalle C.; Rivolta I.; Bauer D.; Oegema R.; Nava C.; Parrini E.; Mei D.; Mercer C.; Dhamija R.; Chambers C.; Coubes C.; Thevenon J.; Kuentz P.; Julia S.; Pasquier L.; Dubourg C.; Carre W.; Rosati A.; Melani F.; Pisano T.; Giardino M.; Innes A.M.; Alembik Y.; Scheidecker S.; Santos M.; Figueiroa S.; Garrido C.; Fusco C.; Frattini D.; Spagnoli C.; Binda A.; Granata T.; Ragona F.; Freri E.; Franceschetti S.; Canafoglia L.; Castellotti B.; Gellera C.; Milanesi R.; Mancardi M.M.; Clark D.R.; Kok F.; Helbig K.L.; Ichikawa S.; Sadler L.; Neupauerova J.; Lassuthova P.; Sterbova K.; Laridon A.; Brilstra E.; Koeleman B.; Lemke J.R.; Zara F.; Striano P.; Soblet J.; Smits G.; Deconinck N.; Barbuti A.; DiFrancesco D.; LeGuern E.; Guerrini R.; Santoro B.; Hamacher K.; Thiel G.; Moroni A.; DiFrancesco J.C.; Depienne C.;
Brain 141:3160-3178(2018)
Cited for: VARIANTS GEFSP10 ALA-85; ARG-171; PRO-172; ARG-243; ILE-260; SER-329; CYS-391; SER-391; MET-414; GLN-590; TYR-680 AND GLY-715; VARIANTS DEE24 TYR-143; ILE-153; GLU-261; LEU-305; ASP-391; LEU-397 AND PRO-399; CHARACTERIZATION OF VARIANTS DEE24 ILE-153; LEU-305; ASP-391; LEU-397 AND PRO-399; CHARACTERIZATION OF VARIANTS GEFSP10 ARG-243; SER-329; CYS-391; SER-391; MET-414 AND GLN-590; VARIANTS CYS-264; THR-275 AND ARG-379; INVOLVEMENT IN DEE24; INVOLVEMENT IN GEFSP10; SUBCELLULAR LOCATION; FUNCTION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.